COVAX

Developed for: pneumonia
Investigated by: Beijing Institute of Biological Products Co Ltd. · Center for Disease Control and Prevention, Fujian · China National Biotec Group Company Limited · Guizhou Center for Disease Control and Prevention · Hunan Provincial Center for Disease Control and Prevention

today NCT05065879 · Ph 4

20222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT05065879	Oct 2021 → Jan 2022	pneumonia	China National Biotec Group Company Limited	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	COVAX	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05065879 ↗